Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Dayvigo

- PMLiVE

AbbVie remains top of immunology sales

But the threat of biosimilars once again threatens to shake up the leader board

- PMLiVE

Relief as study finds no cardiovascular risk with Januvia

FDA continues to investigate safety of numerous diabetes therapies

- PMLiVE

AstraZeneca and PatientsLikeMe team up on real-world data

Two groups hoping to harness the power of the patient forum network

- PMLiVE

Novartis cancer pill makes it onto UK early access list

Joins Merck’s melanoma drug Keytruda for the MHRA’s accelerated review programme 

- PMLiVE

Icelandic genome study yields new disease genes

Nature Medicine study focuses on the probability of developing Alzheimer’s

Biogen Idec building

Biogen Idec claims first with Alzheimer’s candidate

Aducanumab slowed down impairment in cognition and memory in early stages

- PMLiVE

Neurodegenerative research needs better cooperation, say GlobalData

And public funding must be provided to eradicate business risks

- PMLiVE

Another $2m donated to further neurodegenerative commitment

Research funders build on global initiative for brain deteriorating diseases

- PMLiVE

Dementia research alliance to fast-track new Alzheimer’s drugs

Will see Alzheimer's Research UK partner with Cambridge, Oxford and UCL universities

- PMLiVE

AB Science on track for phase III data in Alzheimer’s this year

Trial of masitinib has passed a futility test

- PMLiVE

Merck’s hep C drug no longer a ‘breakthrough’

FDA rescinds designation for grazoprevir/elbasvir due to approval of other treatments

- PMLiVE

Ebola vaccine halt ‘a precaution’ say researchers

Some patients have reported joint pains

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links